MX2019005715A - Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso. - Google Patents

Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.

Info

Publication number
MX2019005715A
MX2019005715A MX2019005715A MX2019005715A MX2019005715A MX 2019005715 A MX2019005715 A MX 2019005715A MX 2019005715 A MX2019005715 A MX 2019005715A MX 2019005715 A MX2019005715 A MX 2019005715A MX 2019005715 A MX2019005715 A MX 2019005715A
Authority
MX
Mexico
Prior art keywords
methods
solid forms
compound
butylamino
carboxamide
Prior art date
Application number
MX2019005715A
Other languages
English (en)
Inventor
Man Hon-Wah
Li Ying
Xu Jean
Hilgraf Robert
a nagy Mark
Georges Beauchamps Marie
christian ferretti Antonio
Huang Lianfeng
Muslehiddinoglu Jale
Hin- Yeong Yong Kelvin
Atul Kothare Mohit
Zhou Nanfei
Andrew Boersen Nathan
Zou Daozhong
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005715(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2019005715A publication Critical patent/MX2019005715A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en la presente formulaciones, proceso, formas sólidas y métodos de uso relacionados con 2-(ter-butilamino)-4-((1 R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamid a (Compuesto I). En otro aspecto, se proporcionan en la presente métodos para preparar ciertos compuestos, incluyendo el Compuesto 1 como se describe en la presente, así como intermediarios útiles en tales métodos. En ciertos aspectos, las formas sólidas del Compuesto I son útiles para inhibir una cinasa en una célula que expresa la cinasa, por ejemplo, JNK1 o JNK2. En otro aspecto, las formas sólidas del Compuesto I son útiles para tratar o prevenir uno o más trastornos seleccionados a partir de fibrosis pulmonar intersticial, esclerosis sistémica, escleroderma, nefropatía de aloinjerto crónica, rechazo mediado por anticuerpo, o lupus.
MX2019005715A 2014-01-30 2016-07-29 Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso. MX2019005715A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461933636P 2014-01-30 2014-01-30
US201462025161P 2014-07-16 2014-07-16

Publications (1)

Publication Number Publication Date
MX2019005715A true MX2019005715A (es) 2019-08-12

Family

ID=53678405

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016009989A MX2016009989A (es) 2014-01-30 2015-01-29 Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.
MX2020003173A MX2020003173A (es) 2014-01-30 2015-01-29 Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.
MX2019005715A MX2019005715A (es) 2014-01-30 2016-07-29 Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016009989A MX2016009989A (es) 2014-01-30 2015-01-29 Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.
MX2020003173A MX2020003173A (es) 2014-01-30 2015-01-29 Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.

Country Status (31)

Country Link
US (6) US9365524B2 (es)
EP (2) EP3738954A1 (es)
JP (3) JP2017504632A (es)
KR (2) KR102505677B1 (es)
CN (3) CN106163523A (es)
AU (2) AU2015211036B2 (es)
BR (2) BR112016017776A8 (es)
CA (1) CA2938187C (es)
CL (1) CL2016001927A1 (es)
CR (1) CR20160346A (es)
CY (1) CY1123267T1 (es)
DK (1) DK3099302T3 (es)
EA (2) EA031671B1 (es)
ES (1) ES2811834T3 (es)
HR (1) HRP20201244T1 (es)
HU (1) HUE051266T2 (es)
IL (2) IL246931B (es)
LT (1) LT3099302T (es)
MX (3) MX2016009989A (es)
MY (1) MY180020A (es)
NZ (3) NZ715903A (es)
PE (1) PE20161437A1 (es)
PH (1) PH12016501472A1 (es)
PL (1) PL3099302T3 (es)
PT (1) PT3099302T (es)
RS (1) RS60715B1 (es)
SA (1) SA516371578B1 (es)
SG (1) SG11201606054SA (es)
SI (1) SI3099302T1 (es)
TW (1) TWI631108B (es)
WO (1) WO2015116755A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351754B (es) 2011-04-22 2017-10-27 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas.
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100308A1 (en) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA3210612A1 (en) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3795553B1 (en) 2015-07-24 2024-05-15 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (zh) 2019-05-13 2021-10-26 华为技术有限公司 天线装置及移动终端

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
US6797706B1 (en) 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JPWO2003082855A1 (ja) 2002-03-28 2005-08-04 協和醗酵工業株式会社 抗炎症剤
CN1665789A (zh) 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
WO2004053071A2 (en) * 2002-12-09 2004-06-24 Judith Kelleher-Andersson Method for discovering neurogenic agents
AU2003289330A1 (en) 2002-12-13 2004-07-09 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
WO2004067516A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
WO2005016894A1 (en) 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005030216A1 (en) 2003-09-24 2005-04-07 Wyeth Holdings Corporation 5-arylpyrimidines as anticancer agents
US7956060B2 (en) 2004-03-30 2011-06-07 Kyowa Hakko Kirin Co., Ltd. Pyrimidine derivative compound
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
AU2005281736A1 (en) 2004-09-10 2006-03-16 Altana Pharma Ag Roflumilast and syk inhibitor combination and methods of use thereof
JP2008512428A (ja) 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドとＳｙｋインヒビターとの組合せ物並びにその使用方法
MX2007003796A (es) 2004-09-30 2007-04-25 Tibotec Pharm Ltd Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
MX2007010102A (es) 2005-03-10 2007-10-12 Bayer Pharmaceuticals Corp Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
KR20090031787A (ko) 2006-07-21 2009-03-27 노파르티스 아게 Ｊａｋ 키나제 억제제로서의 ２,４-디(아릴아미노)-피리미딘-５-카르복스아미드 화합물
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
EA016679B1 (ru) 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
AU2008244026A1 (en) 2007-04-27 2008-11-06 Astrazeneca Ab N' - (phenyl) -N- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as EphB4 kinase inhibitors for the treatment of proliferative conditions
CN101796046A (zh) 2007-07-16 2010-08-04 阿斯利康(瑞典)有限公司 嘧啶衍生物934
JP5586460B2 (ja) 2007-07-17 2014-09-10 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｐｋｃ阻害剤としての環状アミン置換ピリミジンジアミン
EA024109B1 (ru) * 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
KR20170051521A (ko) 2008-04-16 2017-05-11 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
JP5644499B2 (ja) 2008-09-01 2014-12-24 アステラス製薬株式会社 ２，４−ジアミノピリミジン化合物
MX2011002825A (es) 2008-09-18 2011-04-05 Astellas Pharma Inc Compuestos heterociclicos de carboxamida.
US20100137313A1 (en) 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
RU2522001C2 (ru) 2008-10-31 2014-07-10 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
AU2010219097A1 (en) 2009-01-13 2011-08-04 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase
ES2635504T3 (es) 2009-01-21 2017-10-04 Rigel Pharmaceuticals, Inc. Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
DK3009428T3 (en) * 2009-05-08 2018-03-26 Astellas Pharma Inc HETEROCYCLIC DIAMINO-CARBOXAMIDE COMPOUND
EP2440548A1 (en) 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
CA2780759A1 (en) * 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
CA2801781C (en) 2010-07-21 2018-02-27 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
WO2012044936A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
US20130237493A1 (en) 2010-09-30 2013-09-12 Portola Pharmaceuticals, Inc. Combination therapy of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
MX351754B (es) 2011-04-22 2017-10-27 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas.
US9321763B2 (en) * 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
JP6357167B2 (ja) * 2012-12-04 2018-07-11 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびそれらの用途
JP6421170B2 (ja) * 2013-03-14 2018-11-07 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
ES2812605T3 (es) * 2013-12-20 2021-03-17 Signal Pharm Llc Compuestos de diaminopirimidilo sustituidos, composiciones de los mismos y procedimientos de tratamiento con ellos
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CA3210612A1 (en) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2016123291A1 (en) * 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
IL275305B (en) 2021-12-01
EA201792281A1 (ru) 2018-03-30
US20190167678A1 (en) 2019-06-06
US20150210650A1 (en) 2015-07-30
KR102505677B1 (ko) 2023-03-03
WO2015116755A2 (en) 2015-08-06
EP3099302A2 (en) 2016-12-07
US20200078359A1 (en) 2020-03-12
AU2020202146B2 (en) 2021-11-18
JP7317768B2 (ja) 2023-07-31
MX2020003173A (es) 2022-03-30
SG11201606054SA (en) 2016-08-30
NZ629885A (en) 2016-04-29
US10517873B2 (en) 2019-12-31
CN113717110A (zh) 2021-11-30
US20220378785A1 (en) 2022-12-01
DK3099302T3 (da) 2020-08-24
JP2019142893A (ja) 2019-08-29
CR20160346A (es) 2016-11-23
CA2938187C (en) 2022-08-09
CA2938187A1 (en) 2015-08-06
IL275305A (en) 2020-07-30
PL3099302T3 (pl) 2021-03-08
MX2016009989A (es) 2017-02-20
AU2015211036B2 (en) 2020-05-21
SA516371578B1 (ar) 2019-09-01
CY1123267T1 (el) 2021-12-31
US20180028534A1 (en) 2018-02-01
AU2020202146A1 (en) 2020-04-16
WO2015116755A3 (en) 2015-11-12
AU2015211036A1 (en) 2016-08-11
IL246931A0 (en) 2016-09-29
ES2811834T3 (es) 2021-03-15
NZ761068A (en) 2023-02-24
MY180020A (en) 2020-11-19
US10226461B2 (en) 2019-03-12
BR112016017776A2 (pt) 2017-08-08
EP3099302B1 (en) 2020-06-17
CN106163523A (zh) 2016-11-23
US20160256459A1 (en) 2016-09-08
PH12016501472B1 (en) 2016-08-22
LT3099302T (lt) 2020-09-10
WO2015116755A8 (en) 2016-09-22
JP6742466B2 (ja) 2020-08-19
NZ715903A (en) 2017-06-30
US9365524B2 (en) 2016-06-14
CN113717109A (zh) 2021-11-30
US11241430B2 (en) 2022-02-08
IL246931B (en) 2020-06-30
EA031671B1 (ru) 2019-02-28
EP3099302A4 (en) 2017-10-04
PE20161437A1 (es) 2017-01-07
EP3738954A1 (en) 2020-11-18
SI3099302T1 (sl) 2020-10-30
RS60715B1 (sr) 2020-09-30
HRP20201244T1 (hr) 2020-11-13
JP2020183437A (ja) 2020-11-12
BR112016017776A8 (pt) 2020-06-30
HUE051266T2 (hu) 2021-03-01
BR122020003206B1 (pt) 2023-02-07
EA036964B1 (ru) 2021-01-20
JP2017504632A (ja) 2017-02-09
CL2016001927A1 (es) 2017-02-24
PT3099302T (pt) 2020-08-27
KR20160113269A (ko) 2016-09-28
TWI631108B (zh) 2018-08-01
EA201691544A1 (ru) 2017-01-30
KR20220051440A (ko) 2022-04-26
US9814713B2 (en) 2017-11-14
PH12016501472A1 (en) 2016-08-22
NZ722412A (en) 2022-10-28
TW201615627A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
MX2019005715A (es) Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.
EP3494977A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF LUNG FIBROSE WITH FAT TISSUE EXOSOM OBTAINED FROM STEM CELLS AS AN ACTIVE SUBSTANCE
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
PH12018501065A1 (en) Compounds and compositions useful for treating disorders related to ntrk
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
WO2015179724A8 (en) Angiotensinogen (agt) irna compositions and methods of use thereof
EP3351254A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES, CONTAINING, AS ACTIVE INGREDIENT, STEM CELLS SUPRIMINATING SOD3
EP3315133A4 (en) Composition for treating ischemic diseases or neurogenic inflammatory disorders, containing secretome of neural progenitor cells as active ingredient
EP3233809A4 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
WO2013192049A3 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
EP3250557A4 (en) Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MY189930A (en) Glyt1 inhibitors for use in the treatment of hematological disorders
WO2015197534A3 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
SG10201806450SA (en) PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use
WO2015191640A3 (en) Bicyclic xanthine oxidase inhibitors and methods of use
ZA201704927B (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
WO2017109164A8 (en) AGENTS THAT INHIBIT THE BINDING OF CFH TO CD11b/CD18 AND USES THEREOF
WO2015191635A3 (en) Xanthine oxidase inhibitors and methods of use